Ultragenyx Pharma (RARE) Tops Q2 EPS by 14c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.52), $0.14 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $147.02 million versus the consensus estimate of $123.2 million.
GUIDANCE:
Ultragenyx Pharma sees FY2024 revenue of $530-550 million, versus the consensus of $512 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
- UBS Reiterates Buy Rating on McDonald's (MCD)
- Vericel (VCEL) Tops Q3 EPS by 21c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
